IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

IFM Therapeutics is doubling down on its asset-centric subsidiary model, raising $55.5 million to launch an incubator and up to three new subsidiaries focused on developing small molecules targeted at the innate immune system for oncology and inflammatory disorders.

New investor Omega Funds led the financing, joined by existing investors Atlas Venture and Abingworth. ...